The devastation of HIV/AIDS established fact, and the need for continued scientific inquiry and global awareness of the disease remains critical in the search for a highly effective HIV vaccine. Helps Vaccine 2010 aims to help cultivate a worldwide network of scientific skill to transport the field of HIV vaccine analysis in to the future. AIDS Vaccine 2010 will welcome a large cohort of promising early career scientists both nationally and internationally through meeting scholarships and travel support.Net product sales decreased 38 percent to $2.2 billion in the one fourth, when compared to same period a complete year ago. International net sales improved 6 percent to $2.0 billion. Gross margin as a share of net product sales was 74.3 percent in the quarter, in comparison to 74.9 percent in the same period this past year. Marketing, selling and administrative expenditures decreased 6 percent to $1.1 billion in the quarter. Advertising and product promotion spending reduced 26 percent to $212 million in the quarter. Research and advancement expenditures increased 7 percent to $1.1 billion in the quarter. The Company reported a standard tax benefit price of 80.1 percent related to a capital reduction deduction in the one fourth. The effective tax rate on earnings before taxes was 22.8 percent in the fourth quarter this past year.